Purpose: Combined whole-body F-18-fluoro-2-deoxyglucose positron emission tomography / computed tomography ([18F]FDG-PET/CT) gives precise information about tumour morphology and metabolism. The standardized uptake value (SUV) allows quantification of tumour metabolism. The diagnostic value of PET/CT in patients with suspected orbital adnexal lymphoma (OAL) was evaluated. Methods: Of 21 patients with suspected OAL who underwent combined wholebody PET/CT between 07/2002 and 11/2016, 16 were scanned before and five after orbital biopsy. Histological tumour determination was performed in all cases via biopsy. Correlation between SUV max and therapeutic status, lymphoma stage (Ann Arbor classification) and histological grading was tested. Results: All lesions could be depicted by combined whole-body PET/CT. Histology confirmed two malignant T-cell and 18 malignant B cell non-Hodgkin lymphomas as well as one patient suffering from systemic lymphoma with chronic polypoid sinusitis. SUV max levels of orbital findings were significantly lower after therapy (p < 0.001; Fisher's exact test). Higher stage lymphomas (Ann Arbor classification) expressed significantly higher SUV max levels (p = 0.014; Fisher's exact test). There was no significant correlation of SUV max values and histologic grading in this patient collective. Conclusion: Positron emission tomography/computed tomography (PET/CT) depicted vital tumour metabolism of OALs accurately. In cases scanned after orbital biopsy and under systemic therapy, no elevated tumour metabolic activity was expressed. This underlines the reasonable application of PET/CT for therapy monitoring besides whole-body staging. Higher-stage OALs show higher metabolic activity. Yet, for adequate therapy initiation, histology remains indispensable.
Introduction
According to the oncological literature, OALs (ocular adnexal lymphomas) account for 5% of non-Hodgkin lymphomas and 8% of all extranodular lymphomas (Freeman et al. 1972; Bairey et al. 1994 ). In the past two decades, an increasing incidence of ocular non-Hodgkin lymphomas of 6.3% has been reported (Moslehi et al. 2006) . Generally, extraocular lymphomas are very heterogeneous and may become manifest in every part of the orbit or stay isolated in conjunctival tissue or the lacrimal gland. They can demonstrate uni-or bi-lateral growth.
Orbital adnexal lymphoma may manifest primarily or secondarily as metastatic spread of systemic, mostly non-Hodgkin, lymphomas (St€ ubinger 2015) . They can be classified via WHOcriteria histologically (diffuse versus nodular) and via cell-type (B-/T-and natural killer cells). Systemic staging is typically performed by Ann Arbor classification or alternatively via tumour, node, metastases (TNM)-classification (Coupland et al. 2009a,b; Sniegowski et al. 2014) . To obtain optimal therapeutic results in OAL, a structured diagnosis including detailed imaging of tumour localization, primary versus secondary manifestation, isolated ocular versus systemic manifestation, histology and antigenic characteristics is necessary (Kakkassery et al. 2015) . Diagnosis as well as therapy initiation require smooth interdisciplinary teamwork.
As more than 50% of patients suffer from systemic lymphoma manifestation before or at the time of diagnosis of OAL (Jakobiec & Knowles 1989; McKelvie et al. 2001 ), a whole-body imaging modality with high sensitivity and specificity is of essential importance for staging. Local imaging of the OAL should be performed in every case, to assess the involvement of deeper intraorbital structures. For the past decades, magnetic resonance imaging was considered the golden standard besides CT (Polito et al. 1996 ). Yet, they are unable to distinguish reactive lesions from genuine malignant lymphoma (English & Sullivan 2015) . Whole-body staging to differentiate between isolated OAL, further systemic manifestation or systemic lymphoma with ocular manifestation is essential (Coupland et al. 2009a) .
In the past years, combined wholebody F-18-fluoro-2-deoxyglucose positron emission tomography/computed tomography imaging has emerged for the diagnosis and monitoring of patients presenting with different tumour entities (Antoch et al. 2004; Sch€ oder et al. 2004; Haug et al. 2007; Manning et al. 2007 ). Most lymphomas are highly FDG avid (Okada et al. 1991; Bar-Shalom et al. 2000) . Combined whole-body PET/CT is advised as part of standard staging for orbital lymphoma and OAL and is probably used more widely for this disease than for any other tumours of the eye and orbit (Hui et al. 2012) .
In this paper, in addition to evaluation of whole-body PET/CT for OAL, we wanted to assess correlation of FDG-uptake with therapeutic status, histological grading and lymphoma stage.
Materials and Methods
Patients included were selected retrospectively from our PET/CT database. We searched our PET/CT database via the keywords 'orbit' and 'lymphoma'. All patients presented with suspicion of OAL, either throughout the course of known systemic lymphoma or as an isolated finding, first presented in our clinic between 07/2002 and 11/2016 and were included consecutively (n = 21). -FDG were applied intravenously. The imaging protocol included a low-dose CT scan for attenuation correction of PET imaging data acquired 60 minutes after intravenous administration of the PET tracer, a whole-body PET scan obtained with multiple bed positions, typically ranging from the top of the head to the upper third of the thigh, and a diagnostic contrast-enhanced multi-detector-row CT scan covering the range of the previous PET scan. Using the Philips Gemini PET/CT, low-dose CT scan settings were 20 mA, 140 kV, and 512 9 512 matrix, PET data were acquired with a field-of-view of 10 cm and 3 minutes per bed position, and the diagnostic CT scan was performed with 100-190 mA, depending on the scanned region, 120 kV, collimation 2 9 5 mm, and pitch 1.5, in the venous phase, 75 s after intravenous injection of iodine-containing contrast agent (Ultravist 300; Schering, Berlin, Germany) at a rate of 2.5 ml/s. Similar protocols were applied with the other PET/CT scanners.
In two patients, no contrast agent was employed due to known allergies. The reconstruction of the PET data was performed in 3-D mode, with and without attenuation correction. Computed tomography (CT) data were evaluated alone, after multiplanar reformatting (axial, coronal, sagittal), and as combined PET/CT images as generated in with the Hermes system (Hermes Medical Solutions Ltd, London, UK).
Positron emission tomography (PET) and CT imaging was assessed separately as well as fused and side-byside by one Radiologist and one specialist in Nuclear Medicine in consensus. Evaluation of malignancy on CT was based on tumour morphology and patterns of contrast enhancement. For lymph nodes, CT criteria of malignancy included an axial diameter exceeding 10 mm and/or nodal clustering (three or more lymph nodes adjacent to each other), central necrosis, and/or contrast enhancement. Positron emission tomography (PET) images were evaluated for regions of focally increased glucose uptake, typically with a standardized uptake value (SUV max) exceeding a level of 5. We grouped the SUV max levels of the suspicious lesions as normal (<5), elevated (5-10) and highly elevated (>10) in our analysis.
Lymphomas were classified using the Ann Arbor classification and TNMstaging via the 7th Edition AJCC Cancer Staging Manual (Coupland et al. 2009b 
Results
Twenty-one patients were included in this retrospective analysis. Patients' median age at detection of orbital lymphoma was 66 (range 44-85) years. Eleven patients were male and 10 patients female. Positron emission tomography (PET)/CT, tumour and therapeutic details are presented in detail in Table 1 .
In our patient collective, eight (38%) patients presented with isolated OAL whereas 13 (62%) showed systemic manifestation in whole-body staging. In patients with systemic manifestation, eight (62%) presented with orbital and systemic lymphoma manifestation simultaneously and five (38%) presented with OAL during follow-up 1-7 years after initial systemic lymphoma manifestation.
All patients presented with at least one orbital symptom bringing them to ophthalmologic consultation. Ophthalmological symptoms at initial presentation were exophthalmos in 11 (52%), decrease in best corrected (VA) in 10 (48%), shifting of the globe in seven (33%), relative afferent pupillary defect in two (10%), diplopia in two (10%) and ptosis in one (5%) of patients.
All orbital lesions could be visualized on PET/CT. In 20 patients, the intraorbital finding was manifestation of OAL. In one patient, despite diagnosis of systemic non-Hodgkin T-cell lymphoma, the orbital finding proved to be chronic polypoid sinusitis.
We divided patients into two subgroups: Patients who underwent orbital biopsy median 31 (range 19-56) days prior to whole-body PET/CT imaging (n = 5) and patients (n = 16) in whom biopsy was taken after PET/ CT examination. This was performed due to the possible influence of biopsy on glucose metabolism. Depending on the size of the biopsy taken, one might assume that SUV max could possibly decrease after biopsy in smaller lesions. On the other hand, inflammatory tissue response could potentially also lead to elevated FDG-uptake.
Standardized uptake value (SUV max ) was lower in patients who were staged after systemic therapy compared to patients staged before therapy. This was highly significant (p < 0.001; Fisher's exact test; Fig. 1 ).
Findings were grouped according to their exact histopathological subtype and malignancy was graded in the original histological reports by the pathologist as benign (n = 1), lowgrade malignant lymphoma (n = 12) or high-grade malignant lymphoma (n = 8). Orbital SUV max levels did not correlate significantly with histopathological malignancy grading.
Lymphomas of higher staging (Ann Arbor criteria) expressed significantly higher SUV max levels (p = 0.014; Fisher's exact test; Fig. 2) . Figure 3A shows the example of bilateral intramuscular lesions (SUV max =39.2) in patient 1 suffering from a highly malignant mantle cell lymphoma (stage IVB, T2cN4M1a). This patient also suffered from highly FDG avid pathologic groups of lymph nodes as well as intraspleenal manifestation (Fig. 3B) .
Patient 2 with known systemic manifestation of a non-Hodgkin T-cell lymphoma presented with acute exophthalmos of 3 mm on the left. Due to prediagnosed systemic lymphoma, whole-body imaging was performed and CT showed the destruction of the medial orbital wall and intraorbital as well as intranasopharyngeal prolapse caused by the lesion in question. Clinically and radiologically, this is not typical for OAL. Positron emission tomography (PET) imaging did not show elevated tracer uptake (SUV max ) and therefore OAL was ruled out (Fig. 4) . Orbital biopsy proved chronic polypoid sinusitis which was independent from pre-existing lymphoma. Yet, whole-body PET/CT confirmed a single hypermetabolic group of inguinal lymph nodes (stage IA) resulting from systemic lymphoma manifestation (SUV max ≤5.6) in this patient.
Discussion
Combined PET/CT allows assessment of metabolism and morphologic data in one single examination. Our study group previously evaluated wholebody PET/CT for different divisions of Ophthalmic Oncology: On the one hand, whole-body [18F]-FDG PET/CT can be employed for detection of metastasis and therapy monitoring in uveal melanoma patients (Klingenstein et al. 2010 ). On the other hand, we could demonstrate excellent sensitivity of PET/CT for the assessment of orbital tumours and tumours invading the orbit. Different radiopharmaceutical tracers have given evidence of proving metabolic lineage of orbital metastases (Klingenstein et al. 2016) . [68 Ga]-DOTA-TATE 4, 7, N', N'', acid-d-Phe(1), Tyr(3)-octreotate) has proven invaluable for non-invasive diagnostics of meningioma (Klingenstein et al. 2015) .
For the OAL patients included in this study, combined whole-body PET/CT proved to be a sensitive imaging modality for initial staging as well as therapy monitoring of OAL enabling both accurate morphological and metabolic evaluation. FDG PET/CT seems to be of particular benefit for the assessment of extranodal lymphoid tissue (Johnson et al. 2015; Sin et al. 2017) . For orbital and OAL, use of PET/CT has been proven to be feasible and is now accepted both as a standard part of the initial staging work-up and for the assessment of response to therapy (Hui et al. 2012) . We could show that in OAL, post-therapeutic SUV was significantly lower than SUV prior to therapy. This is in accordance with the literature where change in SUV between baseline and interim PET has been reported to serve to quantify metabolic response and furthermore to have prognostic implications (Johnson et al. 2015) .
Corresponding with our data, PET/ CT seems to have high advantages for lymphoma monitoring as the tumour metabolism decreases under treatment. Sixty-two per cent of patients included in this study suffered from systemic lymphoma manifestation, which again correlates with the published data to date (Jakobiec & Knowles 1989; McKelvie et al. 2001) . Out of these patients, again 62% of patients presented with OAL and systemic lymphoma simultaneously emphasizing the importance of PET/CT for monitoring lymphoma patients. PET/CT also enables whole-body staging of OAL patients and therapy response can thus be visualized via imaging. Whole-body PET/CT staging should include the neurocranium and the orbit in patients with suspected systemic lymphoma and orbital symptoms (e.g. exophthalmos, decrease in best corrected visual acuity (BCVA), diplopia etc.). In the remaining 38% of patients, orbital lymphoma manifested 1-7 years after initial diagnosis of systemic lymphoma. Consequently, imaging of patients with prediagnosed systemic lymphoma and orbital symptoms with high image resolution of the orbit (implemented by as small 'field-of-view') should be performed.
One could argue that clinically, destruction of the medial orbital wall and intraorbital structures as well as intranasopharyngeal prolapse of a lesion as in patient 2 is not typical for OAL. Yet, although rare, OAL is capable of local, intracranial, nasopharyngeal, sinus and bony invasion (English & Sullivan 2015) and in this case, PET/CT proved true negative. In combination with whole-body staging that showed avid lymph node manifestation, PET/CT demonstrated great value in this case.
PET metabolism showed no significant difference between histologically graded lymphomas in low or high malignancy. We would explain this to such a degree as high metabolic activity (visualized by high SUV max values) is also expected in the active stage of lowgrade lymphomas. This is when clinical symptoms are most likely to develop. Correlation of the cell proliferation index would therefore be of interest for future studies. In conclusion, orbital biopsy remains indispensable as histologic malignancy does not seem to correlate with metabolic activity, especially considering initiation of adequate systemic therapy.
An interdisciplinary approach for diagnosis, monitoring and the treatment of OAL is of utmost importance. 
